fMRI Cholinergic Mechanisms in Schizophrenia

This study has been completed.
Information provided by (Responsible Party):
Department of Veterans Affairs Identifier:
First received: August 27, 2010
Last updated: November 3, 2014
Last verified: October 2014

This study aims to determine how clozapine treatment improves neuronal measures of sensory gating in subjects with schizophrenia.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: fMRI Cholinergic Mechanisms in Schizophrenia

Resource links provided by NLM:

Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • Neuronal response during sensory gating [ Time Frame: Immediate ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: October 2008
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Group 1
Group 2
Patients with schizophrenia treated with clozapine

Detailed Description:

This study will use functional magnetic resonance imaging (fMRI) to study patients treated with risperidone, a commonly used neuroleptic that does not improves sensory gating, to those treated with clozapine to determine which brain areas are involved in clozapine's normalization of sensory gating in schizophrenia.


Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Subjects with schizophrenia


Inclusion Criteria:

  • Diagnosis of schizophrenia
  • age 18-60 yrs

Exclusion Criteria:

  • claustrophobia
  • weight > 250 lbs
  • metal in body other than dental fillings
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01191827

United States, Colorado
VA Eastern Colorado Health Care System, Denver
Denver, Colorado, United States, 80220
Sponsors and Collaborators
Principal Investigator: Jason R. Tregellas, PhD VA Eastern Colorado Health Care System, Denver
  More Information

No publications provided

Responsible Party: Department of Veterans Affairs Identifier: NCT01191827     History of Changes
Other Study ID Numbers: MHBB-011-07F
Study First Received: August 27, 2010
Last Updated: November 3, 2014
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Mental Disorders
Schizophrenia and Disorders with Psychotic Features processed this record on March 26, 2015